Photo: Female researcher using a machine in the lab


Ocrelizumab was licensed by the European Medicines Agency in January 2018.

>> Read more about this licence

In March 2017 ocrelizumab was approved by the US Food and Drug Administration (FDA) as a treatment for both relapsing and primary progressive MS.

Ocrelizumab is an intravenous infusion treatment that has been developed by Roche.

Current phase of trial: Licensed

Type of MS: primary progressive and relapsing MS

Find out more about ocrelizumab

  • How does ocrelizumab work?
  • How is ocrelizumab taken?
  • Latest research
  • Earlier research
  • What are the side effects of ocrelizumab?
  • How does ocrelizumab compare with current therapies?
  • When will ocrelizumab be available?